Prospective, longitudinal studies of patients with COPD are needed in which plasma YKL-40 is determined several times during follow-up and related to clinical characteristics, e.g. loss of FEV1. The gene discussed is CHI3L1; the disease is chronic obstructive pulmonary disease.